Emoxipin
Emoxipin: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. Drug interactions
- 12. Analogs
- 13. Terms and conditions of storage
- 14. Terms of dispensing from pharmacies
- 15. Reviews
- 16. Price in pharmacies
Latin name: Emoxipine
ATX code: S01XA (eye drops 1%, solution for injection), C05CX [solution for intravenous (IV) and intramuscular (IM) administration]
Active ingredient: methylethylpiridinol (methylethylpiridinol)
Producer: Moscow Endocrine Plant, FERMENT Company (Russia), Tallinn Pharmaceutical Plant (Estonia)
Description and photo updated: 2018-26-11
Prices in pharmacies: from 160 rubles.
Buy
Emoxipin is an antioxidant drug; improves microcirculation, reduces capillary permeability, has an angioprotective, antihypoxant effect.
Release form and composition
Dosage forms of Emoxipin:
- solution for intravenous and intramuscular administration: slightly colored or colorless transparent liquid (1 ml or 5 ml in ampoules: in a cardboard box 5 ampoules; 5 ampoules in contour plastic packaging, in a cardboard box 1, 2, 20, 50 or 100 packs);
- solution for injection: transparent liquid without color (1 ml in ampoules: in a carton pack of 5 ampoules; 5 ampoules in contour plastic packs, in a carton pack of 1, 2, 20, 50 or 100 packs);
- eye drops 1%: slightly colored or colorless liquid with slight opalescence (5 ml each: in glass vials with a dropper cap, in a cardboard box 1 bottle; in bottles, in a cardboard box 1 bottle complete with a dropper cap).
1 ml of solution for intravenous and intramuscular administration contains:
- active substance: methylethylpyridinol hydrochloride (emoxipin) - 30 mg;
- auxiliary components: sodium hydroxide solution 1 M, water for injection.
1 ml of solution for injection contains:
- active substance: methylethylpyridinol hydrochloride - 10 mg;
- auxiliary components: hydrochloric acid OD M, water for injection.
1 ml drops contain:
- active substance: methylethylpyridinol hydrochloride - 10 mg;
- auxiliary components: potassium dihydrogen phosphate, water-soluble methyl cellulose, sodium benzoate, sodium hydrogen phosphate dodecahydrate, sodium sulfite anhydrous, water for injection.
Pharmacological properties
Pharmacodynamics
Emoxipin is a drug with antioxidant, angioprotective, antihypoxant properties. The active substance - methylethylpyridinol, reduces the permeability of the vascular wall, blood viscosity and platelet aggregation, has fibrinolytic activity. Inhibits free radical processes. Increases the content of cyclic nucleotides (adenosine monophosphate and guanosine monophosphate) in platelets and brain tissue, reduces the risk of hemorrhage and promotes their faster resorption.
In cases of acute ischemic disorders of cerebral circulation, it reduces the severity of neurological symptoms, increases tissue resistance to hypoxia and ischemia.
The use of a solution for intravenous and intramuscular administration helps to improve the contractility and function of the cardiac conduction system, to limit the size of the necrosis focus in the acute period of myocardial infarction. Expands coronary vessels, in patients with high blood pressure - has a hypotensive effect.
The retinoprotective properties of Emoxipin make it possible to protect the retina when it is damaged by high-intensity light. In ophthalmology, the drug is used for resorption of intraocular hemorrhages, improvement of eye microcirculation. Eye drops cause a decrease in capillary permeability, strengthen the walls of blood vessels, and help stabilize the cell membrane.
Pharmacokinetics
With intravenous and intramuscular administration, the volume of distribution of emoxipin is 5.2 liters, the clearance is 214.8 ml / min. Metabolism of methylethylpyridinol occurs in the liver. It is excreted through the kidneys. The half-life is 18 minutes.
After instillation of Emoxipin in the eye, the active substance is rapidly absorbed into its tissue. Plasma protein binding is about 42%. In the eye tissue, the deposition and metabolism of methylethylpyridinol occurs with the formation of 5 metabolites in the form of dealkylated and conjugated products of its conversion. It is excreted through the kidneys in the form of metabolites. The concentration of the drug in the tissues of the eye is higher than in the blood.
Indications for use
Solution for i / v and i / m administration
The use of Emoxipin in neurology, cardiology and neurosurgery is indicated as part of the complex therapy of the following diseases and conditions:
- ischemic stroke;
- hemorrhagic stroke in the recovery period;
- transient disorders of cerebral circulation;
- chronic cerebral circulation insufficiency;
- acute myocardial infarction;
- unstable angina;
- prevention of reperfusion syndrome;
- traumatic brain injury;
- the period after surgery for hematoma (epidural, subdural, intracerebral), combined with a contusion of the brain resulting from traumatic brain injury.
Injection
- subconjunctival and intraocular hemorrhage of various origins;
- angioretinopathy, including diabetic retinopathy;
- peripheral and central chorioretinal dystrophy of the retina;
- angiosclerotic macular degeneration (dry form);
- dystrophic pathologies of the cornea;
- thrombosis of the central retinal vein and its branches;
- complications of myopia;
- surgical interventions on the eyes;
- condition after surgery for glaucoma, complicated by detachment of the choroid;
- burn, trauma, inflammation of the cornea;
- protection of the cornea when wearing contact lenses;
- protection of eyes from the effects of high-intensity light (solar radiation, laser).
Eye drops
- treatment of hemorrhages in the anterior chamber of the eye;
- thrombosis of the central retinal vein and its branches;
- diabetic retinopathy;
- prevention and treatment of burns and inflammation of the cornea;
- prevention and treatment of scleral hemorrhages in elderly patients;
- treatment of complications of myopia.
Contraindications
- period of pregnancy;
- lactation;
- age up to 18 years;
- hypersensitivity to the components of Emoxipin.
Instructions for the use of Emoxipin: method and dosage
Solution for i / v and i / m administration
The solution is used by intramuscular and intravenous drip.
The solution for infusion is prepared immediately before the procedure by dissolving the prescribed dose of Emoxipin in 200 ml of isotonic sodium chloride solution.
Recommended dosage for use in neurological and neurosurgical practice: intravenous drip - at the rate of 10 mg per 1 kg of patient weight per day. The infusion rate should not exceed 20-30 drops per minute. The duration of the course is 10-12 days. Then Emoxipin is injected intramuscularly at 60-300 mg 2-3 times a day for 20 days.
The recommended dosage for use in cardiology: intravenous drip at a rate of 20-40 drops per minute - 600-900 mg 1-3 times a day. The duration of the course depends on the course of the disease and can be from 5 to 15 days. Then Emoxipin is administered intramuscularly 2-3 times a day at a dose of 60-300 mg, the course of treatment is from 10 to 30 days.
Injection
The solution is used by subconjunctival, parabulbar and retrobulbar administration.
Recommended dosage:
- subconjunctival injection: 2–5 mg (0.2–0.5 ml) once a day or every other day. The duration of the course is from 10 to 30 days;
- parabulbar injection: 5-10 mg (0.5-1 ml) once a day or every other day. The course of treatment is 10-30 days;
- retrobulbar injection: 5-10 mg (0.5-1 ml) once a day for 10-15 days.
With laser coagulation (including limiting and destructive coagulation of tumors) in order to protect the retina, parabulbar or retrobulbar administration of Emoxipin at a dose of 5-10 mg is indicated 24 hours and 1 hour before coagulation. After the procedure, the initial dose of the drug should be administered once a day for 2-10 days.
If necessary, repeat the treatment 2-3 times during the year.
Eye drops
Emoxipin eye drops are instilled into the conjunctival sac.
To use the drug, you must open the bottle, put the supplied dropper cap on the neck. For instillation, the bottle is turned upside down with a dropper and pressed on its body. After each procedure, close the bottle tightly with a small cap.
Recommended dosage: 1-2 drops 2-3 times a day. The duration of the course is from 3 to 30 days.
With good tolerance, if necessary, treatment can be continued up to 180 days.
According to clinical indications, the course can be repeated 2-3 times a year.
Side effects
Solution for intravenous and intramuscular injection and solution for injection
- local reactions: pain, burning, itching at the injection site;
- from the nervous system: agitation, drowsiness;
- on the part of the cardiovascular system: increased blood pressure (BP);
- from the immune system: allergic reactions.
In addition, the following undesirable phenomena may develop:
- solution for intravenous and intramuscular administration: pain in the region of the heart, headache, disorders of the gastrointestinal tract in the form of dyspepsia, blood clotting disorders;
- injection solution: local reactions - hyperemia, transient compaction of paraorbital tissues.
Eye drops
- possibly: burning sensation, short-term conjunctival hyperemia, itching;
- rarely: local allergic reactions.
Overdose
Overdose symptoms have not been established.
special instructions
Parenteral use of Emoxipin should be accompanied by careful monitoring of blood pressure and blood clotting parameters.
With the simultaneous use of several funds in the form of eye drops, the instillation of Emoxipin must be carried out last, 15 minutes or more after the instillation of the previous drug. Wait until the other drops are completely absorbed so as not to interfere with the pharmaceutical properties of methylethylpyridinol.
The formation of foam as a result of involuntary shaking of the bottle with drops does not affect the quality of the solution, after a while the foam disappears.
Application during pregnancy and lactation
According to the instructions, Emoxipin is contraindicated for use during gestation and during breastfeeding.
Pediatric use
It is contraindicated to use any form of Emoxipin for the treatment of children under the age of 18.
Drug interactions
The simultaneous use of Emoxipin with other drugs leads to a violation or complete loss of its therapeutic efficacy.
Analogs
Emoxipin analogs are: solution for infusion - Emoxipin-Akti; eye drops - Emoxipin-AKOS, Emoxy-optician; solution for intravenous and intramuscular administration - Emoxibel, Cardioxipin; solution for injection - Methylethylpyridinol, Methylethylpyridinol-Eskom.
Terms and conditions of storage
Keep out of the reach of children.
Store at temperatures up to 25 ° C in a dark place.
Shelf life: solution for injection - 3 years, eye drops, solution for intravenous and intramuscular administration - 2 years. After opening the bottle, the drops should be used within a month.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Emoxipin
Reviews about Emoxipin are positive. Patients and doctors note the high efficiency of the drug when used for monotherapy and as part of the complex treatment of serious ophthalmic diseases, the consequences of strokes and heart attacks, and various manifestations of neurological disorders.
The disadvantages of the solution for injections include severe irritation at the injection site, Emoxipin eye drops - temporary discomfort in the form of burning.
Price for Emoxipin in pharmacies
The price of Emoxipin for a package containing 10 ampoules of solution for injection can range from 183 rubles, 1 bottle of eye drops - from 179 rubles.
Emoxipin: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Emoxipin (for injection) 10 mg / ml solution for injection 1 ml 10 pcs. RUB 160 Buy |
|
Emoxipin 1% eye drops 5 ml 1 pc. 199 RUB Buy |
|
Emoxipin 1% eye drops 5 ml 1 pc. 232 RUB Buy |
|
Emoxipin eye drops 1% fl. 5 ml 244 RUB Buy |
|
Emoxipin solution for in. 1% 1ml 10 pcs. 305 RUB Buy |
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
